BACKGROUND AND OBJECTIVE: To assess the treatment response and predictive factors following eplerenone treatment in chronic central serous chorioretinopathy (CSCR). PATIENTS AND METHODS: A prospective, nonrandomized study involving fixed-dose eplerenone was conducted in 22 eyes of 11 consecutive patients with bilateral chronic CSCR. The changes in subretinal fluid (SRF), central macular thickness (CMT), and best-corrected visual acuity (BCVA) were analyzed. RESULTS: A significant reduction in SRF was observed in 13 of 16 eyes with baseline SRF (81.25%) at 3 months (P < .04), with complete resolution in six eyes (37.5%) at 3 months and in 10 eyes (62.5%) at 6 months (P < .006). Baseline BCVA was a significant predictor of final BCVA (P < .001), whereas 3-month SRF height was a weak but significant predictor of the 6-month height (r2 = 0.53; P = .002). CONCLUSION: When treated with eplerenone, chronic CSCR shows a significant reduction in SRF, with baseline BCVA and 3-month SRF height being important predictive factors. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:479-486.]. Copyright 2018, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: To assess the treatment response and predictive factors following eplerenone treatment in chronic central serous chorioretinopathy (CSCR). PATIENTS AND METHODS: A prospective, nonrandomized study involving fixed-dose eplerenone was conducted in 22 eyes of 11 consecutive patients with bilateral chronic CSCR. The changes in subretinal fluid (SRF), central macular thickness (CMT), and best-corrected visual acuity (BCVA) were analyzed. RESULTS: A significant reduction in SRF was observed in 13 of 16 eyes with baseline SRF (81.25%) at 3 months (P < .04), with complete resolution in six eyes (37.5%) at 3 months and in 10 eyes (62.5%) at 6 months (P < .006). Baseline BCVA was a significant predictor of final BCVA (P < .001), whereas 3-month SRF height was a weak but significant predictor of the 6-month height (r2 = 0.53; P = .002). CONCLUSION: When treated with eplerenone, chronic CSCR shows a significant reduction in SRF, with baseline BCVA and 3-month SRF height being important predictive factors. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:479-486.]. Copyright 2018, SLACK Incorporated.
Authors: Camila Q Felipe; Ana Luiza Biancardi; Vinicius T Civile; Nelson Carvas Junior; Pedro D Serracarbassa; Marcia K Koike Journal: Int J Retina Vitreous Date: 2022-06-07
Authors: Hamid-Reza Moein; Lauren W Bierman; Eduardo A Novais; Carlos Moreira-Neto; Caroline R Baumal; Adam Rogers; Jay S Duker; André J Witkin Journal: Int J Retina Vitreous Date: 2019-09-09
Authors: Maciej Gawęcki; Agnieszka Jaszczuk-Maciejewska; Anna Jurska-Jaśko; Małgorzata Kneba; Andrzej Grzybowski Journal: J Clin Med Date: 2019-09-06 Impact factor: 4.241